COMBINATION DRUG THERAPY
A novel combination comprising the17 α-hydroxylase/C17,20 lyase inhibitor, (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3K inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carbo...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BLACKMAN, SAMUEL CHARLES GRESHOCK, JOEL BACHMAN, KURTIS EARL |
| description | A novel combination comprising the17 α-hydroxylase/C17,20 lyase inhibitor, (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3K inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or PI3K is beneficial, e.g., cancer.
L'invention concerne une nouvelle association pharmacologique comprenant l'inhibiteur de 17 α-hydroxylase/C17,20 lyase, le (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol ou un sel ou solvate pharmaceutiquement acceptable, avec un inhibiteur de la PI3K , l'acide 2-méthyl-1-{[2-méthyl-3-(trifluorométhyl)phényl]méthyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylique, ou un sel pharmaceutiquement acceptable. L'invention concerne également des compositions pharmaceutiques comprenant ladite association et des méthodes d'utilisation de ce type d'association et de compositions pour traiter des pathologies dans lesquelles l'inhibition de la 17 α-hydroxylase/C17,20 lyase et/ou de la PI3K est bénéfique, par exemple le cancer. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2015042027A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2015042027A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2015042027A13</originalsourceid><addsrcrecordid>eNrjZJBw9vd18vRzDPH091NwCQp1VwjxcA1yDIjkYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBoamBiZGBkbmjobGxKkCAHcRIJ8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION DRUG THERAPY</title><source>esp@cenet</source><creator>BLACKMAN, SAMUEL CHARLES ; GRESHOCK, JOEL ; BACHMAN, KURTIS EARL</creator><creatorcontrib>BLACKMAN, SAMUEL CHARLES ; GRESHOCK, JOEL ; BACHMAN, KURTIS EARL</creatorcontrib><description>A novel combination comprising the17 α-hydroxylase/C17,20 lyase inhibitor, (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3K inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or PI3K is beneficial, e.g., cancer.
L'invention concerne une nouvelle association pharmacologique comprenant l'inhibiteur de 17 α-hydroxylase/C17,20 lyase, le (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol ou un sel ou solvate pharmaceutiquement acceptable, avec un inhibiteur de la PI3K , l'acide 2-méthyl-1-{[2-méthyl-3-(trifluorométhyl)phényl]méthyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylique, ou un sel pharmaceutiquement acceptable. L'invention concerne également des compositions pharmaceutiques comprenant ladite association et des méthodes d'utilisation de ce type d'association et de compositions pour traiter des pathologies dans lesquelles l'inhibition de la 17 α-hydroxylase/C17,20 lyase et/ou de la PI3K est bénéfique, par exemple le cancer.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150326&DB=EPODOC&CC=WO&NR=2015042027A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150326&DB=EPODOC&CC=WO&NR=2015042027A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BLACKMAN, SAMUEL CHARLES</creatorcontrib><creatorcontrib>GRESHOCK, JOEL</creatorcontrib><creatorcontrib>BACHMAN, KURTIS EARL</creatorcontrib><title>COMBINATION DRUG THERAPY</title><description>A novel combination comprising the17 α-hydroxylase/C17,20 lyase inhibitor, (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3K inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or PI3K is beneficial, e.g., cancer.
L'invention concerne une nouvelle association pharmacologique comprenant l'inhibiteur de 17 α-hydroxylase/C17,20 lyase, le (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol ou un sel ou solvate pharmaceutiquement acceptable, avec un inhibiteur de la PI3K , l'acide 2-méthyl-1-{[2-méthyl-3-(trifluorométhyl)phényl]méthyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylique, ou un sel pharmaceutiquement acceptable. L'invention concerne également des compositions pharmaceutiques comprenant ladite association et des méthodes d'utilisation de ce type d'association et de compositions pour traiter des pathologies dans lesquelles l'inhibition de la 17 α-hydroxylase/C17,20 lyase et/ou de la PI3K est bénéfique, par exemple le cancer.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJBw9vd18vRzDPH091NwCQp1VwjxcA1yDIjkYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx4f5GBoamBiZGBkbmjobGxKkCAHcRIJ8</recordid><startdate>20150326</startdate><enddate>20150326</enddate><creator>BLACKMAN, SAMUEL CHARLES</creator><creator>GRESHOCK, JOEL</creator><creator>BACHMAN, KURTIS EARL</creator><scope>EVB</scope></search><sort><creationdate>20150326</creationdate><title>COMBINATION DRUG THERAPY</title><author>BLACKMAN, SAMUEL CHARLES ; GRESHOCK, JOEL ; BACHMAN, KURTIS EARL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2015042027A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2015</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>BLACKMAN, SAMUEL CHARLES</creatorcontrib><creatorcontrib>GRESHOCK, JOEL</creatorcontrib><creatorcontrib>BACHMAN, KURTIS EARL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BLACKMAN, SAMUEL CHARLES</au><au>GRESHOCK, JOEL</au><au>BACHMAN, KURTIS EARL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION DRUG THERAPY</title><date>2015-03-26</date><risdate>2015</risdate><abstract>A novel combination comprising the17 α-hydroxylase/C17,20 lyase inhibitor, (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3K inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or PI3K is beneficial, e.g., cancer.
L'invention concerne une nouvelle association pharmacologique comprenant l'inhibiteur de 17 α-hydroxylase/C17,20 lyase, le (3 )-17-(pyridin-3-yl)androsta-5,16-dien-3-ol ou un sel ou solvate pharmaceutiquement acceptable, avec un inhibiteur de la PI3K , l'acide 2-méthyl-1-{[2-méthyl-3-(trifluorométhyl)phényl]méthyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylique, ou un sel pharmaceutiquement acceptable. L'invention concerne également des compositions pharmaceutiques comprenant ladite association et des méthodes d'utilisation de ce type d'association et de compositions pour traiter des pathologies dans lesquelles l'inhibition de la 17 α-hydroxylase/C17,20 lyase et/ou de la PI3K est bénéfique, par exemple le cancer.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2015042027A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | COMBINATION DRUG THERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T21%3A50%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BLACKMAN,%20SAMUEL%20CHARLES&rft.date=2015-03-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2015042027A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |